In comparisons of clinical characteristics between patients with and without bone metastases, the 31 patients with metastatic bone lesions exhibited significantly higher serum prostate-specific antigen levels and Gleason grade group and advanced tumor stage (p < 0.05; Table 1). This evidence concerns the gene KLK3 and neoplasm.